Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing

A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. These organoids behave like miniature versions of the original tumor, preserving the same mix of cell types, genetic changes and androgen‑receptor biology that drive the disease. By building these “mini‑tumors in a dish,” the team has created a low‑cost, clinically relevant platform that can be used to test how individual tumors respond to different drugs, opening the door to more personalized treatment strategies.

The key innovation is that the organoids are grown from tissue that would normally be discarded after surgery, meaning no extra biopsies are needed. The researchers optimized the culture conditions to reduce reliance on expensive serum‑rich media, keeping the organoids closer to the biology of the original tumor. In these models, they see the same genetic alterations commonly found in advanced prostate cancer, including changes in TP53, PTEN, APC and FOXA1, which influence tumor aggression and treatment response. The organoids also maintain androgen‑receptor signaling, which is central to how current hormone‑targeting drugs work. This fidelity suggests they are not just artificial cell lines but genuine surrogates of the disease.

In parallel experiments, the team treated the organoids with the same drugs the patients were receiving in the clinic. The responses in the dish often mirrored what happened in the patients: drugs that shrank tumors in the body tended to reduce organoid growth, while drugs that failed clinically also showed limited effect on the organoids. This match between lab‑model response and clinical outcome highlights the potential of these organoids as a predictive tool, allowing doctors to test several treatment options on a patient’s own tumor cells before choosing a regimen. Because the organoids can be grown relatively quickly from TUR‑P tissue, this approach could be integrated into routine care, especially for men with advanced or treatment‑resistant prostate cancer who are running out of standard options.

Source.